DENVER, Colo., Apr 23, 2024 (247marketnews.com)- Theriva Biologics (NYSE:TOVX) stated that the Company will present preclinical data demonstrating enhanced anti-tumor effects in human pancreatic cancer xenograft-bearing mice treated with lead product candidate VCN-01 and liposomal irinotecan, supporting the potential synergy of VCN-01 and first-line pancreatic cancer chemotherapy regimens, which will be featured in a poster presentation at the American Society for Cell and Gene Therapy (ASGCT) 27^th Annual Meeting, May 7-11, 2024.

"The data featured at the upcoming ASGCT meeting build on recent findings that suggest the combination of VCN-01 and topoisomerase I inhibitors, such as liposomal irinotecan, may provide a synergistic antitumor effect to improve therapeutic outcomes across indications," stated Steven A. Shallcross, Chief Executive Officer of Theriva Biologics. "We look forward to leveraging these findings and evaluating the combination of VCN-01 with additional first-line pancreatic cancer chemotherapy regimens, including NALIRIFOX and FOLFIRINOX. In parallel, we continue to progress our on-going VIRAGE Phase 2b trial evaluating VCN-01 in combination with gemcitabine/nab-paclitaxel to treat metastatic pancreatic ductal adenocarcinoma (PDAC). Together, these important steps bring us one step closer to building a portfolio of potentially improved therapeutic combinations for PDAC patients with high unmet medical needs."

The post Theriva Biologics to Present Preclinical VCN-01 Data at Upcoming ASCGT Annual Meeting appeared first on 24/7 MarketNews.

COMTEX_451345557/2900/2024-04-24T11:16:25